Transgene 
Welcome,         Profile    Billing    Logout  
 11 Products   90 Diseases  11 Products   12 Trials   527 News 
20 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Myodys (TG 5001) / Transgene, Arrowhead
NCT06485661: Effect of Captopril on GLS in Duchenne Myodystrophy

Recruiting
1
20
RoW
Captopril Tablets
Ain Shams University
Effect of Drug
09/24
09/24
Pexa-Vec (pexastimogene devacirepvec) / SillaJen
ACTRN12620001286932: Investigating the effect of a virus-based immunotherapy as a pre-surgical treatment for prostate cancer

Recruiting
2
30
 
Royal Melbourne Hospital, Movember, Medical Research Future Fund
Prostate Cancer
 
 
JX594-REN026, NCT03294083: A Study of Recombinant Vaccinia Virus in Combination With Cemiplimab for Renal Cell Carcinoma

Active, not recruiting
1b/2a
89
US, RoW
Pexastimogene Devacirepvec (Pexa-Vec), JX-594, Cemiplimab
SillaJen, Inc., Regeneron Pharmaceuticals
Renal Cell Carcinoma
08/23
11/23
2016-000085-32: The purpose of this study is to evaluate the safety and efficacy of the combination of two products Pexa-Vec and nivolumab for the treatment of liver cancer L'obiettivo dello studio clinico è di valutare la sicurezza e l'efficacia della combinazione dei due prodotti Pexa-Vec e nivolumab per il trattamento del tumore del fegato

Not yet recruiting
1/2
55
Europe
pexastimogene devacirepvec, nivolumab, [Pexa-Vec], [nivolumab], Suspension for injection, Concentrate for solution for infusion, OPDIVO - 10 MG/ML- CONCENTRATO PER SOLUZIONE PER INFUSIONE- USO ENDOVENOSO- FLACONCINO (VETRO)- 4 ML- 1 FLACONCINO
TRANSGENE SA, TRANSGENE
Hepatocellular carcinoma Carcinoma epatocellulare, Liver cancer Tumore del fegato, Diseases [C] - Cancer [C04]
 
 
NCT03206073: A Phase I/II Study of Pexa-Vec Oncolytic Virus in Combination With Immune Checkpoint Inhibition in Refractory Colorectal Cancer

Checkmark Results in combination with Pexa-Vec with failed MSS and MSI-H colorectal cancer
Jan 2019 - Jan 2019: Results in combination with Pexa-Vec with failed MSS and MSI-H colorectal cancer
Completed
1/2
34
US
Durvalumab, MEDI-4736, Tremelimumab, CP-675,206, Pexa-Vec, Pexa-Vec, INN pexastimogene devacirepvec
National Cancer Institute (NCI)
Colorectal Cancer, Colorectal Carcinoma, Colorectal Adenocarcinoma, Refractory Cancer, Colorectal Neoplasms
09/20
06/22
NCT04849260: Phase Ib/II Clinical Study of Pexa-Vec (Vaccinia GM CSF / Thymidine Kinase-Deactivated Virus) Combined With Recombinant Whole Human Anti-PD-L1 Monoclonal Antibody (ZKAB001) in Metastatic Melanoma

Recruiting
1/2
54
RoW
Pexa-Vec combined with ZKAB001, ZKAB001 monotherapy
Lee's Pharmaceutical Limited
Local Progression or Metastatic Melanoma With Failed First-line Treatment
05/22
05/23
METROmaJX, NCT02630368: A Study of Metronomic CP and JX-594 in Patients With Advanced Breast Cancer and Advanced Soft-tissue Sarcoma

Checkmark Results for HER2-ve breast cancer and soft tissue sarcoma in combination with metronomic cyclophosphamide
Sep 2018 - Sep 2018: Results for HER2-ve breast cancer and soft tissue sarcoma in combination with metronomic cyclophosphamide
Recruiting
1/2
197
Europe
Cyclophosphamide and JX-594 dose escalation, Brand name : ENDOXAN, Brand name: Pexa-Vec, Cyclophosphamide and JX-594, Cyclophosphamide, Avelumab and JX-594 and Cyclophosphamide, Brand name: ENDOXAN, Brand name: Avelumab
Institut Bergonié, National Cancer Institute, France, Fondation ARC, Merck Sharp & Dohme LLC, Transgene
Solid Tumors, Soft-tissue Sarcoma, Breast Cancer
05/23
11/24
tipapkinogene sovacivec (TG4001) / Transgene
TG4001.12, NCT03260023 / 2016-002799-28: Phase Ib/II of TG4001 and Avelumab in HPV16 Positive R/M Cancers

Hourglass Jan 2020 - Jun 2020 : From trial in combination with TG4001
Checkmark Results in combination with TG4001 in Phase 1b part of trial
Dec 2018 - Dec 2018: Results in combination with TG4001 in Phase 1b part of trial
Checkmark First patient enrollment for P1/2 study in combination with TG4001 for HPV-positive HNSCC
Sep 2017 - Sep 2017: First patient enrollment for P1/2 study in combination with TG4001 for HPV-positive HNSCC
Active, not recruiting
1/2
150
Europe, US
TG4001, Avelumab
Transgene, Merck KGaA, Darmstadt, Germany, EMD Serono Research & Development Institute, Inc., Pfizer
HPV-Related Carcinoma, HPV-Related Cervical Carcinoma, HPV-Related Anal Squamous Cell Carcinoma, HPV-Related Penile Squamous Cell Carcinoma, HPV-Related Vulvar Squamous Cell Carcinoma
09/24
12/25
TG1050 / Transgene, Tasly
NCT04189276: Safety and Efficacy of Therapeutic Hepatitis B Adenovirus Injection (T101) Combined With Nucleoside (Acid) Analogues in Chronic Hepatitis B Patients

Active, not recruiting
2
100
RoW
ETV/TDF+T101 No.1, ETV/TDF+T101 No.2, ETV or TDF, ETV/TDF+Peg-IFNα-2b
Tasly Tianjin Biopharmaceutical Co., Ltd.
Hepatitis B Virus (HBV)
06/21
12/21
ChiCTR-IIR-17013776: A phase I, single center, randomized, double-blind, placebo controlled, single dose (SD) and multiple dose (MD), dose-escalation clinical trial to evaluate the tolerability and preliminary antiviral activity of therapeutic hepatitis B adenovirus injection (T101) in chronic hepatitis B patients.

Not yet recruiting
1
36
 
3 different dosage groups are set up, 4 patients in each group will be randomized to receive T101 or placebo, 3 patients will be subcutaneously injected with T101, 1 patient will receive placebo.1 time at day 1, the doses were 1.0E+9, 1.0 E+10, 1.0 E+11 VP or placebo. ;2 different dosage groups are set up，12 patients in each group will be randomized to receive T101 or placebo, 9 patients will be subcutaneously injected with T101, 3 patients will receive placebo.3 times at day 1, day 8 and day15,the doses are 1.0 E+10 and 1.0 E+11 VP or placebo.
Transgene Tasly (Tianjin) BioPharmaceutical Co., Ltd.; Transgene Tasly (Tianjin) BioPharmaceutical Co., Ltd., self-financing
chronic hepatitis B virus (HBV) infection
 
 
TG6002 / Transgene, Tasly
TG6002.03, NCT04194034 / 2018-004103-39: Study of Intrahepatic Arterial Infusion of TG6002 in Combination With 5-FC in Patients With Metastatic Colorectal Cancer

Terminated
2a
15
Europe
TG6002, Flucytosine (5-FC)
Transgene
Colorectal Neoplasms
02/23
02/23
NCT04226066: Safety, Tolerability and Pharmacokinetics Characteristics of Recombinant Oncolytic Vaccinia Virus Injection T601 as a Single Drug or in Combination With Oral Flucytosine (5-FC), in Patients With Advanced Malignant Solid Tumors

Recruiting
1/2
69
RoW
T601, T601+5-FC
Tasly Tianjin Biopharmaceutical Co., Ltd.
Advanced Malignant Solid Tumors
05/21
05/22
NCT03724071 / 2018-000039-28: Study of TG6002 (VV TK-RR-FCU1) in Combination With 5-FC in Patients With Advanced Gastro-intestinal Tumors.

Terminated
1/2
51
Europe
TG6002, Flucytosine (5-FC, Ancotil)
Transgene
Colorectal Neoplasm, Digestive System Neoplasm
02/23
02/23
TG4050 / Transgene, NEC Corp
TG4050.02, NCT04183166: A Clinical Trial Evaluating TG4050 in Head and Neck Cancer

Active, not recruiting
1/2
80
Europe, US
TG4050
Transgene
Squamous Cell Carcinoma of Head and Neck
12/27
12/28
NCT03839524: A Trial Evaluating TG4050 in Ovarian Carcinoma.

Completed
1
64
Europe, US
TG4050
Transgene
Ovarian Carcinoma, Fallopian Tube Cancer, Peritoneal Carcinoma
10/24
10/24
BT-001 / BioInvent, Transgene
2020-000505-80: A phase I/IIa clinical study of BT-001 in the treatment of patients withmetastatic or advanced solid cancer. Etude clinique de Phase I/IIa évaluant BT-001 chez des patients présentant des tumeurs solides avancées ou métastatiques.

Not yet recruiting
1/2
258
Europe
Pembrolizumab, BT-001, Solution for injection, Powder for concentrate for solution for infusion, Keytruda (pembrolizumab)
TRANSGENE, TRANSGENE, BioInvent International AB (publ)
Phase I: Advanced or metastatic Soft Tissue Sarcoma, Merkel Cell Carcinoma, Melanoma, Triple Negative Breast Cancer, Non Smal Cell Lung Cancer Phase IIa: Soft Tissue Sarcoma, Merkel Cell Carcinoma, Melanoma, Triple Negative Breast Cancer, Non Smal Cell Lung Cancer Phase I: Tumeurs solides avancées ou métastatiques incluant les sarcomes des tissus mous, carcinome à cellules de Merkel, mélanome, cancer du sein triple négatif ou cancer du poumon non à petites cellulesPhase IIa: Sarcomes des tissus mous, carcinome à cellules de Merkel, mélanome, cancer du sein triple négatif ou cancer du poumon non à petites cellules, Advanced or metastatic solid tumors Tumeurs solides avancées ou métastatiques, Diseases [C] - Cancer [C04]
 
 
KEYNOTE-E37, NCT04725331 / 2020-000505-80: A Clinical Trial Assessing BT-001 Alone and in Combination With Pembrolizumab in Metastatic or Advanced Solid Tumors

Recruiting
1/2
48
Europe
BT-001, Pembrolizumab [KEYTRUDA®], KEYTRUDA®
Transgene, BioInvent International AB, Merck Sharp & Dohme LLC
Metastatic Cancer, Soft Tissue Sarcoma, Merkel Cell Carcinoma, Melanoma, Triple Negative Breast Cancer, Non Small Cell Lung Cancer
04/25
04/25
SP-002 / Stamford Pharma
NCT04416516: Safety and Efficacy of ASN-002 Combined With a Hedgehog Pathway Inhibitor

Completed
2
21
RoW
ASN-002
Ascend Biopharmaceuticals Ltd
Basal Cell Carcinoma, Basal Cell Nevus Syndrome
02/24
02/24
NCT06344052: To Assess the Safety and Efficacy of SP-002 with Vismodegib for the Treatment of Locally Advanced Basal Cell Carcinoma

Recruiting
2
80
US
SP-002, Vismodegib
Stamford Pharmaceuticals, Inc.
Basal Cell Carcinoma
09/26
03/29
TG6050 / Transgene
Delivir, NCT05788926: A Clinical Trial of TG6050 in Patients With Metastatic Non-Small Cell Lung Cancer

Recruiting
1
36
Europe
TG6050
Transgene
Non-small Cell Lung Cancer
04/25
10/25
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Myodys (TG 5001) / Transgene, Arrowhead
NCT06485661: Effect of Captopril on GLS in Duchenne Myodystrophy

Recruiting
1
20
RoW
Captopril Tablets
Ain Shams University
Effect of Drug
09/24
09/24
Pexa-Vec (pexastimogene devacirepvec) / SillaJen
ACTRN12620001286932: Investigating the effect of a virus-based immunotherapy as a pre-surgical treatment for prostate cancer

Recruiting
2
30
 
Royal Melbourne Hospital, Movember, Medical Research Future Fund
Prostate Cancer
 
 
JX594-REN026, NCT03294083: A Study of Recombinant Vaccinia Virus in Combination With Cemiplimab for Renal Cell Carcinoma

Active, not recruiting
1b/2a
89
US, RoW
Pexastimogene Devacirepvec (Pexa-Vec), JX-594, Cemiplimab
SillaJen, Inc., Regeneron Pharmaceuticals
Renal Cell Carcinoma
08/23
11/23
2016-000085-32: The purpose of this study is to evaluate the safety and efficacy of the combination of two products Pexa-Vec and nivolumab for the treatment of liver cancer L'obiettivo dello studio clinico è di valutare la sicurezza e l'efficacia della combinazione dei due prodotti Pexa-Vec e nivolumab per il trattamento del tumore del fegato

Not yet recruiting
1/2
55
Europe
pexastimogene devacirepvec, nivolumab, [Pexa-Vec], [nivolumab], Suspension for injection, Concentrate for solution for infusion, OPDIVO - 10 MG/ML- CONCENTRATO PER SOLUZIONE PER INFUSIONE- USO ENDOVENOSO- FLACONCINO (VETRO)- 4 ML- 1 FLACONCINO
TRANSGENE SA, TRANSGENE
Hepatocellular carcinoma Carcinoma epatocellulare, Liver cancer Tumore del fegato, Diseases [C] - Cancer [C04]
 
 
NCT03206073: A Phase I/II Study of Pexa-Vec Oncolytic Virus in Combination With Immune Checkpoint Inhibition in Refractory Colorectal Cancer

Checkmark Results in combination with Pexa-Vec with failed MSS and MSI-H colorectal cancer
Jan 2019 - Jan 2019: Results in combination with Pexa-Vec with failed MSS and MSI-H colorectal cancer
Completed
1/2
34
US
Durvalumab, MEDI-4736, Tremelimumab, CP-675,206, Pexa-Vec, Pexa-Vec, INN pexastimogene devacirepvec
National Cancer Institute (NCI)
Colorectal Cancer, Colorectal Carcinoma, Colorectal Adenocarcinoma, Refractory Cancer, Colorectal Neoplasms
09/20
06/22
NCT04849260: Phase Ib/II Clinical Study of Pexa-Vec (Vaccinia GM CSF / Thymidine Kinase-Deactivated Virus) Combined With Recombinant Whole Human Anti-PD-L1 Monoclonal Antibody (ZKAB001) in Metastatic Melanoma

Recruiting
1/2
54
RoW
Pexa-Vec combined with ZKAB001, ZKAB001 monotherapy
Lee's Pharmaceutical Limited
Local Progression or Metastatic Melanoma With Failed First-line Treatment
05/22
05/23
METROmaJX, NCT02630368: A Study of Metronomic CP and JX-594 in Patients With Advanced Breast Cancer and Advanced Soft-tissue Sarcoma

Checkmark Results for HER2-ve breast cancer and soft tissue sarcoma in combination with metronomic cyclophosphamide
Sep 2018 - Sep 2018: Results for HER2-ve breast cancer and soft tissue sarcoma in combination with metronomic cyclophosphamide
Recruiting
1/2
197
Europe
Cyclophosphamide and JX-594 dose escalation, Brand name : ENDOXAN, Brand name: Pexa-Vec, Cyclophosphamide and JX-594, Cyclophosphamide, Avelumab and JX-594 and Cyclophosphamide, Brand name: ENDOXAN, Brand name: Avelumab
Institut Bergonié, National Cancer Institute, France, Fondation ARC, Merck Sharp & Dohme LLC, Transgene
Solid Tumors, Soft-tissue Sarcoma, Breast Cancer
05/23
11/24
tipapkinogene sovacivec (TG4001) / Transgene
TG4001.12, NCT03260023 / 2016-002799-28: Phase Ib/II of TG4001 and Avelumab in HPV16 Positive R/M Cancers

Hourglass Jan 2020 - Jun 2020 : From trial in combination with TG4001
Checkmark Results in combination with TG4001 in Phase 1b part of trial
Dec 2018 - Dec 2018: Results in combination with TG4001 in Phase 1b part of trial
Checkmark First patient enrollment for P1/2 study in combination with TG4001 for HPV-positive HNSCC
Sep 2017 - Sep 2017: First patient enrollment for P1/2 study in combination with TG4001 for HPV-positive HNSCC
Active, not recruiting
1/2
150
Europe, US
TG4001, Avelumab
Transgene, Merck KGaA, Darmstadt, Germany, EMD Serono Research & Development Institute, Inc., Pfizer
HPV-Related Carcinoma, HPV-Related Cervical Carcinoma, HPV-Related Anal Squamous Cell Carcinoma, HPV-Related Penile Squamous Cell Carcinoma, HPV-Related Vulvar Squamous Cell Carcinoma
09/24
12/25
TG1050 / Transgene, Tasly
NCT04189276: Safety and Efficacy of Therapeutic Hepatitis B Adenovirus Injection (T101) Combined With Nucleoside (Acid) Analogues in Chronic Hepatitis B Patients

Active, not recruiting
2
100
RoW
ETV/TDF+T101 No.1, ETV/TDF+T101 No.2, ETV or TDF, ETV/TDF+Peg-IFNα-2b
Tasly Tianjin Biopharmaceutical Co., Ltd.
Hepatitis B Virus (HBV)
06/21
12/21
ChiCTR-IIR-17013776: A phase I, single center, randomized, double-blind, placebo controlled, single dose (SD) and multiple dose (MD), dose-escalation clinical trial to evaluate the tolerability and preliminary antiviral activity of therapeutic hepatitis B adenovirus injection (T101) in chronic hepatitis B patients.

Not yet recruiting
1
36
 
3 different dosage groups are set up, 4 patients in each group will be randomized to receive T101 or placebo, 3 patients will be subcutaneously injected with T101, 1 patient will receive placebo.1 time at day 1, the doses were 1.0E+9, 1.0 E+10, 1.0 E+11 VP or placebo. ;2 different dosage groups are set up，12 patients in each group will be randomized to receive T101 or placebo, 9 patients will be subcutaneously injected with T101, 3 patients will receive placebo.3 times at day 1, day 8 and day15,the doses are 1.0 E+10 and 1.0 E+11 VP or placebo.
Transgene Tasly (Tianjin) BioPharmaceutical Co., Ltd.; Transgene Tasly (Tianjin) BioPharmaceutical Co., Ltd., self-financing
chronic hepatitis B virus (HBV) infection
 
 
TG6002 / Transgene, Tasly
TG6002.03, NCT04194034 / 2018-004103-39: Study of Intrahepatic Arterial Infusion of TG6002 in Combination With 5-FC in Patients With Metastatic Colorectal Cancer

Terminated
2a
15
Europe
TG6002, Flucytosine (5-FC)
Transgene
Colorectal Neoplasms
02/23
02/23
NCT04226066: Safety, Tolerability and Pharmacokinetics Characteristics of Recombinant Oncolytic Vaccinia Virus Injection T601 as a Single Drug or in Combination With Oral Flucytosine (5-FC), in Patients With Advanced Malignant Solid Tumors

Recruiting
1/2
69
RoW
T601, T601+5-FC
Tasly Tianjin Biopharmaceutical Co., Ltd.
Advanced Malignant Solid Tumors
05/21
05/22
NCT03724071 / 2018-000039-28: Study of TG6002 (VV TK-RR-FCU1) in Combination With 5-FC in Patients With Advanced Gastro-intestinal Tumors.

Terminated
1/2
51
Europe
TG6002, Flucytosine (5-FC, Ancotil)
Transgene
Colorectal Neoplasm, Digestive System Neoplasm
02/23
02/23
TG4050 / Transgene, NEC Corp
TG4050.02, NCT04183166: A Clinical Trial Evaluating TG4050 in Head and Neck Cancer

Active, not recruiting
1/2
80
Europe, US
TG4050
Transgene
Squamous Cell Carcinoma of Head and Neck
12/27
12/28
NCT03839524: A Trial Evaluating TG4050 in Ovarian Carcinoma.

Completed
1
64
Europe, US
TG4050
Transgene
Ovarian Carcinoma, Fallopian Tube Cancer, Peritoneal Carcinoma
10/24
10/24
BT-001 / BioInvent, Transgene
2020-000505-80: A phase I/IIa clinical study of BT-001 in the treatment of patients withmetastatic or advanced solid cancer. Etude clinique de Phase I/IIa évaluant BT-001 chez des patients présentant des tumeurs solides avancées ou métastatiques.

Not yet recruiting
1/2
258
Europe
Pembrolizumab, BT-001, Solution for injection, Powder for concentrate for solution for infusion, Keytruda (pembrolizumab)
TRANSGENE, TRANSGENE, BioInvent International AB (publ)
Phase I: Advanced or metastatic Soft Tissue Sarcoma, Merkel Cell Carcinoma, Melanoma, Triple Negative Breast Cancer, Non Smal Cell Lung Cancer Phase IIa: Soft Tissue Sarcoma, Merkel Cell Carcinoma, Melanoma, Triple Negative Breast Cancer, Non Smal Cell Lung Cancer Phase I: Tumeurs solides avancées ou métastatiques incluant les sarcomes des tissus mous, carcinome à cellules de Merkel, mélanome, cancer du sein triple négatif ou cancer du poumon non à petites cellulesPhase IIa: Sarcomes des tissus mous, carcinome à cellules de Merkel, mélanome, cancer du sein triple négatif ou cancer du poumon non à petites cellules, Advanced or metastatic solid tumors Tumeurs solides avancées ou métastatiques, Diseases [C] - Cancer [C04]
 
 
KEYNOTE-E37, NCT04725331 / 2020-000505-80: A Clinical Trial Assessing BT-001 Alone and in Combination With Pembrolizumab in Metastatic or Advanced Solid Tumors

Recruiting
1/2
48
Europe
BT-001, Pembrolizumab [KEYTRUDA®], KEYTRUDA®
Transgene, BioInvent International AB, Merck Sharp & Dohme LLC
Metastatic Cancer, Soft Tissue Sarcoma, Merkel Cell Carcinoma, Melanoma, Triple Negative Breast Cancer, Non Small Cell Lung Cancer
04/25
04/25
SP-002 / Stamford Pharma
NCT04416516: Safety and Efficacy of ASN-002 Combined With a Hedgehog Pathway Inhibitor

Completed
2
21
RoW
ASN-002
Ascend Biopharmaceuticals Ltd
Basal Cell Carcinoma, Basal Cell Nevus Syndrome
02/24
02/24
NCT06344052: To Assess the Safety and Efficacy of SP-002 with Vismodegib for the Treatment of Locally Advanced Basal Cell Carcinoma

Recruiting
2
80
US
SP-002, Vismodegib
Stamford Pharmaceuticals, Inc.
Basal Cell Carcinoma
09/26
03/29
TG6050 / Transgene
Delivir, NCT05788926: A Clinical Trial of TG6050 in Patients With Metastatic Non-Small Cell Lung Cancer

Recruiting
1
36
Europe
TG6050
Transgene
Non-small Cell Lung Cancer
04/25
10/25

Download Options